Pregled bibliografske jedinice broj: 536103
Maternal Efficacy and Safety Outcomes in a Randomized Trial Comparing Insulin Detemir with NPH Insulin in 310 Pregnant Women with Type 1 Diabetes
Maternal Efficacy and Safety Outcomes in a Randomized Trial Comparing Insulin Detemir with NPH Insulin in 310 Pregnant Women with Type 1 Diabetes // American Diabetes Association, 71st Scientific Sessions
San Diego (CA): American Diabetes Association, 2011. (predavanje, nije recenziran, sažetak, znanstveni)
CROSBI ID: 536103 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Maternal Efficacy and Safety Outcomes in a Randomized Trial Comparing Insulin Detemir with NPH Insulin in 310 Pregnant Women with Type 1 Diabetes
Autori
Mathiesen, Elisabeth R ; Damm, Peter ; Hod, Moshe ; Mccance, David R ; Ivanišević, Marina ; Duran-Garcia, Santiago ; Jovanovic, Lois
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
American Diabetes Association, 71st Scientific Sessions
Mjesto i datum
San Diego (CA), Sjedinjene Američke Države, 24.06.2011. - 28.06.2011
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Nije recenziran
Ključne riječi
Detemir; HPH insulin; perinatal outcome
Sažetak
Results: The aim of this prospective, randomized, controlled, parallel-group, open-label trial was to compare the efficacy and safety of insulin detemir (IDet) vs. NPH (both with prandial insulin aspart) in pregnant women with type 1 diabetes (T1DM). T1DM women (HbA1c ≤8 % at pregnancy confirmation) were randomized to IDet (n=152) or NPH (n=158) up to 12 months before pregnancy or during pregnancy at 8-12 weeks gestation. The primary objective was to confirm efficacy of IDet by showing that IDet was non-inferior to NPH with respect to HbA1c at 36 gestational weeks (GWs) (primary endpoint). Non-inferiority was shown if the upper limit of the 95% CI for the treatment difference of IDet vs. NPH was below the pre-specified non-inferiority margin of 0.4% for both the Full Analysis Set (FAS) and Per Protocol Set (PP). The data were analyzed using linear regression. 79 and 83 women in the IDet and NPH groups, respectively, were pregnant at randomization while 73 and 75 women, respectively, became pregnant following randomization. Mean±SD baseline demographics were: age 30.1±4.4 yrs ; BMI 24.8±4.1 kg/m2 ; HbA1c 7.01±0.79% ; fasting plasma glucose (FPG) 5.94±3.25 mmol/l and diabetes duration 12.3±8.0 yrs. For FAS, the estimated HbA1c at GW36 was 6.27% for IDet and 6.33% for NPH. IDet was declared non-inferior to NPH (FAS: -0.06%, 95% CI: -0.21 ; 0.08 ; PP: -0.151% ; 95% CI: -0.34 ; 0.04). FPG was significantly lower with IDet vs. NPH (table). Hypoglycemia rates were similar between groups. In summary, lower FPG, but comparable HbA1c in late pregnancy were obtained using insulin detemir in comparison to NPH insulin in women with type 1 diabetes.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1080401-0385 - Dijabetes i metabolički sindrom nakon prethodnog gestacijskog dijabetesa (Ivanišević, Marina, MZOS ) ( CroRIS)
108-1080401-0386 - Metaboličke i endokrine promjene u dijabetičnih trudnica (Đelmiš, Josip, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Marina Ivanišević
(autor)